AbbVie won an expected FDA approval for its next-generation treatment for hepatitis C, kicking off a race with Gilead Sciences for dominance in a blockbuster field.
As 2014 winds down, and Gilead Sciences keeps winding up hep C sales by the billion, AbbVie waits, vibrating with anticipation. Its three-drug cocktail is up for FDA approval any day now, and the Illinois-based company is ready to challenge Gilead for market share.
The Federal Trade Commission is urging a Pennsylvania federal court to move forward with its pay-for-delay lawsuit against AbbVie, rejecting the company's arguments that it did not keep a generic version of its testosterone powerhouse AndroGel off the market and contending that the suit meets a precedent set last year by the U.S. Supreme Court.
The ripple effects of AbbVie's canceled Shire deal extend beyond the disgruntled hedge fund managers and spooked investors who've been making noise since the $55 billion buyout collapsed. Several large investment banks lost money, too, raising eyebrows over whether they're illegally betting their own funds.
Indian drugmaker Zydus Cadila has launched a biosimilar of Humira in its home market--the first in a long line of in-development copies to threaten AbbVie's powerhouse med.
In biotech, here are the top 10 news stories of the year so far, based on web traffic.
AbbVie is one step closer to challenging Gilead Sciences' dominance in the hepatitis C market, securing a likely European approval for its rival combo treatment as it awaits a U.S. nod.
French startup Enterome Bioscience has been inking deals and raking in funds to develop its personalized microbiome tests. Now, the company is teaming up with AbbVie to create molecular diagnostic tools that will help find the best therapies for patients with Crohn's disease.
The EMA responded quickly to the publication of the letter, issuing a release to outline its approach to the redaction of commercial confidential information.
AbbVie can count this among the consequences of canceling its Shire buyout: Deal-focused hedge funds are losing investors.